Khusrow Niazi, MD
Interventional Cardiology · Atlanta, GANPI 1215949961
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.8%), speaking fees and education — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 42.3% of the total. Reporting peaked in 2024 at $701 and has fallen 79.6% since, to $143 in 2025. That places this record below the midpoint for interventional cardiology clinicians in GA, where the typical reported total is $7,640.
Across 10 payments — averaging $118.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$500
- GE HealthCare$210
- Boston Scientific$185
- Cordis US CORP.$169
- Johnson & Johnson$46
- Abiomed$32
- plus $39 from 2 others
Across 193 payments — averaging $2086.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Surmodics, Inc.$106K
- M.a. Med Alliance S.A.$103K
- Trireme Medical LLC$97K
- Bard Peripheral Vascular, Inc.$69K
- Philips North America LLC$24K
- Boston Scientific$3K
- plus $2K from 1 others
What the payments were for
- Speaking & faculty fees$50042%
- Food & beverage$63554%
- Education$464%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 1 | $500 |
| GE HealthCare | 1 | $210 |
| Boston Scientific | 2 | $185 |
| Cordis US CORP. | 1 | $169 |
| Johnson & Johnson | 1 | $46 |
| Abiomed | 2 | $32 |
| Imperative Care, Inc | 1 | $26 |
| Angiodynamics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SELUTION SLRPTA$169
- ROTAPRO$117
How this compares
$1,181 in reported general payments places this provider in the 5th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 22 | $28,706 |
| XareltoRivaroxaban | 18 | $20,584 |
| Praluent PenAlirocumab | 30 | $14,457 |
| BrilintaTicagrelor | 16 | $14,203 |
| Repatha SyringeEvolocumab | 12 | $6,344 |
| Ezetimibe | 22 | $819 |
| Nifedipine ErNifedipine | 25 | $784 |
| Rosuvastatin Calcium | 32 | $639 |
| Metoprolol Succinate | 58 | $552 |
| Atorvastatin Calcium | 73 | $512 |
| ClopidogrelClopidogrel Bisulfate | 79 | $480 |
| Amlodipine Besylate | 66 | $453 |
| Losartan Potassium | 70 | $307 |
| Nitroglycerin | 17 | $263 |
| Valsartan | 16 | $244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $46 | $20,58418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Atlanta
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Adam GreenbaumAtlanta$238K
- Wissam JaberAtlanta$222K
- Katherine KunkelAtlanta$189K
- James StewartAtlanta$174K
- Pratik SandesaraAtlanta$165K
- Chandanreddy DevireddyAtlanta$121K
- Prashant KaulAtlanta$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.